Navigation Links
Elekta's Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
Date:2/25/2011

ATLANTA, Feb. 25, 2011 /PRNewswire/ -- Elekta's MOSAIQ®* oncology electronic medical record (EMR) has received complete EMR certification. Complete EMR certification officially validates the Elekta software and enables eligible providers to qualify to demonstrate Stage 1 meaningful use under the HITECH Act.  

Tested and certified under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Testing and Certification Body (ONC-ATCB) program, the EMR software is Stage 1 compliant with criteria adopted by the Secretary of Health and Human Services. The complete certification of MOSAIQ makes it the first comprehensive, oncology EMR to receive this important certification.

"MOSAIQ is a popular solution in many of the world's leading cancer care facilities, so certification is a huge step for this software and puts our customers at the front of the line for incentive funds," says Todd Powell, Executive Vice President, Elekta Software. "We have worked to make MOSAIQ not only the most comprehensive, interoperable and robust solution available, but also equipped it to perform functions that all modern EMRs should have to increase efficiency in patient care. Certification is additional evidence of these efforts."

Drummond Group's ONC-ATCB 2011/2012 certification program tests and certifies that EMRs meet the meaningful use criteria for either eligible provider or hospital technology. In turn, healthcare providers using the EMR systems of certified vendors are qualified to receive federal stimulus monies available under the HITECH Act upon demonstrating meaningful use of the technology – a key component of the federal government's push to improve clinical care delivery through the adoption and effective use of EMRs by U.S. healthcare providers.

In addition to providing a certified EMR, Elekta offers custom programs through its STRATEGIQ™ consultative services to help clients prepare to demonstrate meaningful use.

"Whether an existing MOSAIQ user seeking to qualify for incentives or a new customer wanting to adopt the Elekta EMR solution, STRATEGIQ experts can conduct a thorough audit of a cancer center's operations, then provide an action plan specific to their needs," says Powell. "The oncology field requires specific workflows and processes unique to the profession, and it is important that sites – from practices with a single clinician to groups with more than 100 physicians – develop an implementation plan that ensures success."

Leveraging more than 20 years of leadership and expertise of IMPAC Medical Systems, MOSAIQ is the tool of choice to manage cutting-edge treatment centers. Learn more about the world's most widely used oncology EMR at www.elekta.com/MOSAIQ.

This EHR module is 2011/2012 compliant to prove meaningful use under the HITECH Act and is certified by an ONC-ATCB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services or guarantee the receipt of incentive payments. MOSAIQ was certified February 25, 2011, Certification ID number 02252011-1018-6 for Clinical Quality Measures: NQF0013, NQF0024, NQF0028, NQF0038, NQF0041, NQF0385, NQF0387, NQF0389, NQF0421. No additional software used

*MOSAIQ® is a registered trademark of its manufacturer, IMPAC Medical Systems, Inc.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible. Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
2. Healthcare Providers Rate Elektas MOSAIQ Oncology Information System as No. 1 in 2010 KLAS Report
3. Elekta Introduces MOSAIQ Data Director, Image and Data Hub for Oncology
4. Cancer Treatment Centers Oncology Information System Options Expand with New MOSAIQ Connectivity
5. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., ... From Not to Hot,” which will begin airing on February 24, 2017. The show ... from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... CALNOC, the ... FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in ... chairman and CEO of the Virginia Mason Health System in Seattle since 2000. In ...
(Date:2/23/2017)... ... 2017 , ... Thomas Vas-Don suffered from severe injury due to ... able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” ... principals of massage, anatomy , trigger points and referral pain patterns . ...
Breaking Medicine News(10 mins):